Includes patients

Heart Failure with Preserved Ejection Fraction (IL-6 Study)

Location: Solmed Polyclinic (Zagreb)

Study Drug: Experimental drug that reduces inflammation throughout the body, which should strengthen the heart’s function.

Main Inclusion Criteria: Adult patients diagnosed with heart failure and a concentration of NT-proBNP in the blood >300 pg/ml, with an ejection fraction (EF) on echocardiography >40%.

Status: Enrolling new patients

Start of patient enrollment: November 2023

Planned completion of new patient enrollment: November 2024

Check if you are a candidate for a free examination

Related

Cardiology and angiology

Atrial Fibrillation

Study Drug: Experimental drug that slows blood clotting, inhibitor of coagulation factor XI. This experimental drug is expected to have equal effectiveness in preventing stroke with a lower risk of bleeding, the most common side effect of this drug class.

More
Cardiology and angiology, Neurology

Postural Orthostatic Tachycardia Syndrome (POTS)

Study Drug: Biological therapy that suppresses the excessive activity of B-lymphocytes that overly produce antibodies associated with this syndrome. The drug is already registered for the treatment of myasthenia gravis.

More
Cardiology and angiology, Endocrinology, diabetes and metabolic diseases

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Study Drug: A drug from the PCSK9 inhibitor group, already registered for treating elevated lipids. It is available to patients who have had a myocardial infarction and, with existing medications, have excessively high LDL cholesterol. In the context of this study, the drug can be given to patients who have not had a myocardial infarction but are at a high risk of it.

More
Cardiology and angiology

Heart Attack (Myocardial Infarction)

Study Drug: Experimental drug that slows blood clotting, an inhibitor of clotting factor XI. A low dose of this experimental drug is expected to prevent the reformation of clots at the site of previous blood vessel blockage.

More
Cardiology and angiology

Heart Failure with Preserved Ejection Fraction (MRA Study)

Study Drug: Mineralocorticoid receptor antagonist, already registered for the treatment of other diseases.

More
Cardiology and angiology, Endocrinology, diabetes and metabolic diseases

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Study Drug: Experimental drug “transfers” cholesterol from bad particles (LDL) to good particles (HDL) of cholesterol.

More

Testimonials from
our patients

Poliklinika Solmed

Lidija Reškovac

“Izuzetno sam zadovoljna interakcijom – mogu saznati sve o bolesti i liječenju.”

Poliklinika Solmed

Siniša Kvakić

“Prijava putem upitnika na web stranici je veoma jednostavna.”

Poliklinika Solmed

Zvonimir Rogina

“Uključivanje u naše studije je jednostavno i intuitivno.”

Newsletter

Receive regular notifications about our activities and news in treatments.

Free examinations